Ligand Pharmaceuticals to acquire APEIRON Biologics AG to enhance royalty portfolio
Acquiring Company
Ligand Pharmaceuticals Incorporated
Acquired Company
APEIRON Biologics AG
San Diego
ViennaBiotechnologyHealthcareHealth CarePharmaceuticalBiopharmaBiotechnologyTherapeuticsBiopharmaDescription
Ligand Pharmaceuticals Incorporated has entered into a definitive agreement to acquire APEIRON Biologics AG for $100 million in cash. This acquisition will add QARZIBA, an immunotherapy for high-risk neuroblastoma, to Ligand's commercial royalty portfolio, providing significant clinical value and generating predictable and long-term revenue streams. In addition, Ligand will pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively.
Other recent acquisitions in Healthcare and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Cycle Pharmaceuticals proposes to acquire Vanda Pharmaceuticals for $8.00 per share (June 6, 2024)
- Edwards Lifesciences Completes Acquisitions of JenaValve Technology and Endotronix (July 24, 2024)
- HEALWELL AI finalizes acquisition of VeroSource Solutions and BioPharma Services to expand healthcare technology capabilities (July 2, 2024)
- AbbVie completes acquisition of Celsius Therapeutics, Inc. to advance therapies for inflammatory disease (June 27, 2024)
- Incyte completes acquisition of Escient Pharmaceuticals to strengthen its Inflammation and Autoimmunity portfolio (May 30, 2024)
- Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease (August 16, 2024)
Who to call at Ligand Pharmaceuticals Incorporated, and when
When Ligand Pharmaceuticals Incorporated changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Ligand Pharmaceuticals Incorporated raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ligand Pharmaceuticals Incorporated, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ligand Pharmaceuticals Incorporated. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ligand Pharmaceuticals Incorporated makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired APEIRON Biologics AG?
APEIRON Biologics AG was acquired by Ligand Pharmaceuticals Incorporated, based in San Diego. The deal was reported on July 8, 2024. Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand Pharmaceuticals Incorporated is publicly traded (LGND) and operates in Biotechnology.
When did Ligand Pharmaceuticals Incorporated acquire APEIRON Biologics AG?
Ligand Pharmaceuticals Incorporated's acquisition of APEIRON Biologics AG was reported on July 8, 2024. Ligand Pharmaceuticals Incorporated has entered into a definitive agreement to acquire APEIRON Biologics AG for $100 million in cash. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does APEIRON Biologics AG do?
APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. It is privately held, operating in Biotechnology, and is based in Vienna.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.